Business
Notice of Results
Genedrive PLC has announced that it will release its preliminary results for the year ended 30 June 2025 on Friday, 5 December 2025, followed by a live investor presentation on Monday, 8 December 2025, at 2pm GMT, hosted via Investor Meet Company. Disclaimer*
About this update from Genedrive Plc
[{"type":"text","content":"\n\n \ngenedrive plc\n(\"genedrive\" or the \"Company\")\n \nNotice of results\nInvestor presentation\n \ngenedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces it will release its preliminary results for the year ended 30 June 2025 on Friday, 5 December 2025.\n \nThe Company will provide a live presentation to accompany the results, presented by CEO, Gino Miele and CFO, Russ Shaw on Monday, 8 December 2025 at 2pm GMT. \n \nThe presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet genedrive plc via the following link: https://www.investormeetcompany.com/genedrive-plc/register-investor \n \nFor further details please contact:\n \n\n\n\n\ngenedrive plc\n\n\n+44 (0)161 989 0245\n\n\n\n\nGino Miele: CEO / Russ Shaw: CFO\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeel Hunt LLP (Nominated Adviser and Broker)\n\n\n+44 (0)20 7418 8900\n\n\n\n\nJames Steel\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Ltd (Media & Investor Relations)\n\n\n+44 (0)20 7933 8780 or [email protected]\n\n\n\n\nAnna Dunphy\n\n\n+44 (0)7876 741 001\n\n\n\n\n \nAbout genedrive plc (http://www.genedriveplc.com)\n \ngenedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use...